### 2025-08-20 Pyridostigmine Improves Hand Grip Strength in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- **Metadata:**
    - **Authors:** Ella Schl√∂mer, Elisa Stein, Claudia Kedor, Rebekka Rust, Anna Brock, Kirsten Wittke, Carmen Scheibenbogen, Laura Kim.
    - **Institutes:** Institute for Medical Immunology, Charit√© University Medicine Berlin, Berlin, Germany; Charite - Universitatsmedizin Berlin Institut fur Medizinische Immunologie, Berlin, Germany; Experimental and Research Center (ECRC), Charit√©-Universit√§tsmedizin Berlin, Berlin, Germany.
    - **Publisher:** Frontiers in Neuroscience
    - **Link:** [DOI](https://doi.org/10.3389/fnins.2025.1637838)
- **What was researched?**
This study investigated the immediate effect of the acetylcholinesterase inhibitor pyridostigmine on muscle strength and orthostatic function in patients with post-infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
- **Why was it researched?**
ME/CFS is often characterized by muscle weakness and fatiguability. Previous research indicated that pyridostigmine üíä improved cardiac output in ME/CFS patients, and the drug is currently used off-label for ME/CFS and POTS. This study aimed to formally evaluate its effects on muscle strength, a key symptom of the illness.
- **How was it researched?**
This was an interventional study involving 20 patients with post-infectious ME/CFS. Researchers measured hand grip strength ten times using an electric dynamometer and repeated the test one hour later to assess fatiguability. In a separate test session, patients received a 30 mg dose of pyridostigmine after the initial measurement, and the test was repeated one hour later to measure the drug's effect. Orthostatic function was also assessed using a passive standing test, and patients were screened to rule out Myasthenia Gravis.
- **What has been found?**
All patients initially showed reduced hand grip strength. Without the drug, strength declined significantly after one hour. In contrast, one hour after taking pyridostigmine, patients showed a median increase of 2.6 kg in maximum hand grip strength. The drug also improved orthostatic function, as shown by a smaller increase in heart rate upon standing (median of 13 bpm with the drug vs. 17 bpm without).
- **Discussion:**
The authors propose that the observed improvements are due to two primary mechanisms. They suggest the drug increases the availability of acetylcholine at neuromuscular junctions, which directly impacts muscle function, and that it also augments parasympathetic tone, which helps regulate autonomic functions like heart rate.
- **Conclusion & Future Work:**
The study concludes that pyridostigmine has an immediate and positive effect on both muscle strength and orthostatic function in ME/CFS patients. The abstract does not specify plans for future work but establishes a clear therapeutic benefit that warrants further investigation.
- **Summary:**
This research provides objective evidence that pyridostigmine, a drug already in use for other conditions, can temporarily improve muscle strength and stabilize heart rate in ME/CFS patients. The findings support a potential role for impaired neuromuscular and autonomic signaling in the disease's symptoms, specifically muscle weakness and orthostatic intolerance. While this was a small-scale study, it validates a pharmacological approach for symptom management and points towards a specific biological mechanism that could be targeted in future treatments.
- **Simple Summary:**
Researchers found that a drug called pyridostigmine immediately improved hand grip strength in ME/CFS patients. The medicine also helped reduce the heart rate increase that happens when standing up. This study suggests the drug may help with muscle weakness and orthostatic symptoms in the illness.